RecruitingNot ApplicableNCT06639854

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Sponsor

M.D. Anderson Cancer Center

Enrollment

105 participants

Start Date

Nov 20, 2024

Study Type

INTERVENTIONAL

Conditions

Hematopoietic Cell Transplant Cytomegalovirus Cell Mediated Immunity

Summary

The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Hematopoietic Cell Transplant and a drug called Letermovir for people with cytomegalovirus cell mediated immunity and hematopoietic cell transplant. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHematopoietic Cell Transplant

Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available. These alternative treatments have risks and benefits that may be the same or different than those in this research study.

DRUGLetermovir

Given by PO